Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Isocapnic Oxygen

Phase 3Biologic

UUniversity of Maryland, Baltimore

Isocapnic Oxygen is one of 43 biologic programs targeting Glaucoma. It is currently in Phase 3.

1

Indications

1

Total Trials

1

Active Trials

42

Competitors

Pipeline

Status by Indication[3][1]

Indication

GlaucomaRecruiting

GlaucomaPhase 3

Recruiting

Competition

Competitive Landscape

54 competitors in Glaucoma

#DrugCompanyPhaseTrials

Alphagan

Zolymbus

Travatan

Xalatan

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Crestor

Timolol Maleate

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Diamox

Neoral

Isopto Carpine

Tobrex

VViatris Specialty LLC

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalRecruiting

Study completion

NCT05344274

Clinical

Trials by Indication[1]

Unspecified1 trial

Retinal Blood Flow and Autoregulation

Recruiting·UUniversity of Maryland, Baltimore·Phase 4·NCT05344274·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Isocapnic Oxygen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Isocapnic Oxygen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Isocapnic Oxygen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Maryland, Baltimore company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Maryland, Baltimore

Related News